1 Old rats are resistant to fibrate-induced hypolipidemia owing to a reduction in hepatic peroxisome proliferator-activated receptor a (PPARa). We tested whether the age-related decrease in PPARa is prevented by atorvastatin (ATV), a hypolipidemic statin. 2 We determined the activity and expression of Liver X receptor a (LXRa) and PPARa in the liver of 18-month-old rats treated with 10 mg kg À1 of ATV for 21 days. We measured fatty acid oxidation (FAO), the expression of PPARa-target genes, liver triglyceride (TG) and cholesteryl ester (CE) contents and plasma concentrations of TG, cholesterol, glucose, nonesterified fatty acids (NEFA), insulin and leptin. While old female rats were practically unresponsive, ATV-treated old males showed lower liver TG (À41%) and CE (À48%), and plasma TG (À35%), glucose (À18%) and NEFA (À39%). Age-related alterations in LXRa expression and binding activity were reverted in ATVtreated old males. These changes were related to an increase in hepatic FAO (1.2-fold), and PPARa mRNA (2.2-fold), PPARa protein (1.6-fold), and PPARa-binding activity. 3 Hepatic nuclear factor-4 (HNF-4) and chicken ovalbumin upstream-transcription factor-II participate in the transcriptional regulation of the PPARa gene, while peroxisome proliferatoractivated receptor gamma coactivator 1 (PGC-1) behaves as a PPAR coactivator. Ageing reduced the hepatic content of HNF-4 (74%) and PGC-1 (77%) exclusively in male rats. ATV administration to old males enhanced the hepatic expression and binding activity (two-fold) of HNF-4. 4 ATV-induced changes in hepatic HNF-4 and PPARa may be responsible for the improvement of the lipid metabolic phenotype produced by ATV administration to senescent male rats.
Introduction
Old age is associated with dyslipidemia, obesity and type 2 diabetes mellitus (Knight, 2001) . In humans, these risk factors, generally referred to as polymetabolic syndrome, increase the risk of a major cardiovascular event in late life (James, 2001 ). Old rats develop many metabolic alterations common to aged humans. Thus, the incidence of dyslipidemia, leptin resistanceassociated obesity and progressive failure of insulin-mediated glucose metabolism is common to aged rats and humans (Grabiely et al., 2002) . We have recently shown that old age strongly reduces the expression and activity of peroxisome proliferator-activated receptor a (PPARa) in the liver of male rats. Therefore, these animals become resistant to the hypotriglyceridemic effect of gemfibrozil, a PPARa ligand belonging to the fibrate class of hypolipidemic drugs (Sanguino et al., 2004b) .
Fibrates and statins are the two most commonly used hypolipidemic drugs. Statins mainly reduce intrahepatocyte cholesterol levels and promote the expression of cell surface apo B/E receptors, thus increasing the clearance of apo Bcontaining lipoproteins and reducing circulating LDL (Moghadasian et al., 2000) . As a rule, all statins reduce plasma triglycerides in proportion to their LDL-lowering efficacy and baseline triglyceride levels (Stein et al., 1998) . However, atorvastatin (ATV), a synthetic statin, is a more potent inhibitor of plasma triglycerides than other statins (BakkerArkema et al., 1996) ; although it increases apo B degradation rates in HepG2 cells, the mechanism responsible for this marked hypotriglyceridemic effect remains unclear (Mohammadi et al., 1998) .
We have recently shown, in an experimental model of hypertriglyceridemia, the fructose-fed rat, that the increase in plasma and liver triglycerides is linked to decreased expression and activity of liver PPARa. Moreover, ATV treatment partially prevented these changes, increasing liver PPARa mRNA levels and hepatic fatty acid b-oxidation activity and thus decreasing hepatic and plasma triglyceride concentrations (Roglans et al., 2002a ). Accordingly, we tested whether ATV also prevents the age-related decrease in hepatic PPARa and several of its target genes (liver-carnitine palmitoyl transferase-I (L-CPT-I) and medium chain acyl-CoA dehydrogenase (MCAD)) observed in old rats. We also determined whether ATV administration reverts the significant changes detected in the hepatic expression and activity of liver X receptor a (LXRa) of senescent male rats (Sanguino et al., 2004a) . Moreover, we have shown that rats present a gender-related lipid metabolic phenotype linked to old age (Sanguino et al., 2004a) , that is, the expression of several key metabolic factors, like LXRa and diacylglycerol acyl transferase (DGAT) isoforms, is differentially affected by age in males and females. Thus, we also tested whether this dimorphic phenotype influences the response to ATV administration. To shed some light on the mechanism behind the age-related decrease in hepatic PPARa, we finally determined the effect of ageing on several hepatic factors influencing PPARa expression, namely chicken ovalbumin upstream transcription factor II (COUP-TFII), hepatic nuclear factor-4 (HNF-4) and peroxisome proliferator-activator receptor gamma coactivator-1 (PGC-1), and their response to ATV administration.
Methods

Animals
Male and female 3-month-and 18-month-old Sprague-Dawley rats were purchased from Criffa (Barcelona, Spain). They were maintained with water and food ad libitum at constant humidity and temperature with a light/dark cycle of 12 h (08:00-20:00 hours) for a minimum of 5 days. After acclimatization, 18-month-old rats were randomly assigned to control and ATV-treated groups (eight animals each group). ATV was included in the diet at a concentration adjusted to the age-dependant daily food consumption in order to provide a daily therapeutic dose of 10 mg kg
À1
. Control and treated diets were prepared as described elsewhere (Alegret et al., 1994) and fed to the animals for 21 days. Young and old animals were weighted and killed by decapitation under ketamine (100 mg kg À1 , i.p.) anaesthesia between 09:00 and 00:10 hours. To reduce the variability in plasma 17b-estradiol concentrations, female rats were killed in the dioestrus period. Blood samples were collected at death in 5% EDTA tubes; plasma was obtained by centrifugation and stored at À801C until needed. Samples of liver, skeletal muscle and heart of each rat (10-100 mg each) were immediately frozen in liquid N 2 and stored at À801C until the extraction of total RNA, quantification of liver lipids and preparation of nuclear extracts and postnuclear fractions. All procedures were conducted in accordance with the principles and guidelines established by the University of Barcelona Bioethics Committee, as stated in Law 5/1995, 21st July, from the Generalitat de Catalunya.
Plasma metabolites and hormones
Plasma glucose, cholesterol and triglycerides were determined using commercial kits (code No. 115-A, 401 and 334-UV, respectively) from Sigma Diagnostics (St Louis, U.S.A.). Non esterified fatty acids (NEFA) were determined using the kit NEFAC code No. 994-75409 from Wako Chemicals (Richmond, U.S.A.). The remaining plasma analytes were determined by RIA using the following commercial kits: RPA 547 from Amersham pharmacia biotech (Barcelona, Spain) for rat insulin and RL83 K from Clonagen (Madrid, Spain) for rat leptin.
Liver lipid content and enzyme assays
Liver triglycerides were extracted and measured as described elsewhere (Verd et al., 1999) , using the 336 triglyceride (INT) Sigma kit (Madrid, Spain). Liver total and free cholesterol were extracted and measured as described elsewhere (Llaverı´as et al., 2002) . Cholesteryl ester concentrations were calculated as the difference between total and free cholesterol. The hepatic fatty acid b-oxidation was determined as described elsewhere (Lazarow, 1981) . In total, 30 mg of postnuclear supernatant of each sample was used for the assay. Protein concentration was determined following Bradford (Bradford, 1976) .
RNA preparation and analysis
Total RNA was isolated using Ultraspec reagent (Biotecx, Houston, U.S.A.). The relative levels of specific mRNAs were assessed by the reverse transcription-polymerase chain reaction (RT-PCR). Complementary DNA was synthesized from RNA samples by mixing 0.5 mg of total RNA (1 mg in the case of PPARa), 125 ng of random hexamers (Roche diagnostics, Indianapolis, U.S.A.) as primers, in the presence of 50 mM Tris-HCl buffer (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol, 200 U Moloney murine leukemia virus reverse transcriptase (Invitrogen, Gaithersburg, U.S.A.), 20 U RNAsin (Invitrogen) and 0.5 mM of each dNTP (Sigma) in a total volume of 20 ml. Samples were incubated at 371C for 60 min. A 5 ml aliquot of the RT reaction was then used for subsequent PCR amplification with specific primers.
Each 50-ml PCR reaction contained 5 ml of the RT reaction, 1.2 mM MgCl 2 , 0.16 mM of each dNTP, 2.5 mCi [a 32 P]-dATP (3000 Ci mmol
À1
, Amersham biosciences), 1 U of Taq polymerase (Invitrogen), 0.5 mg of each primer and 16 mM TrisHCl, pH 8.5. To avoid unspecific annealing, cDNA and Taq polymerase were separated from primers and dNTPs by using a layer of paraffin (reaction components contact only when paraffin fuses, at 601C). The sequences of the sense and antisense primers used for amplification are shown in Table 1 . The adenosyl phosphoribosyl transferase (APRT) gene was used as internal control in the PCR reaction to normalize the results, except for DGAT1. For this gene and for APRT, coamplification was performed in separate tubes and in duplicate. PCR was performed in an MJ Research Thermocycler (Ecogen, Barcelona, Spain) equipped with a peltier system and temperature probe. After initial denaturation for 1 min at 941C, PCR was performed for n cycles (Table 1) . Each cycle consisted of denaturation at 921C for 1 min, primer annealing at 601C and primer extension at 721C for 1 min and 854
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In total, 5 ml of each PCR sample was electrophoresed on a 1-mm-thick 5% polyacrylamide gel. The gels were dried and subjected to autoradiography using Agfa X-ray films (Danny Commercial, Barcelona, Spain) to show the amplified DNA products. Amplification of each gene yielded a single band of the expected size. Preliminary experiments were carried out with various amounts of cDNA to determine the nonsaturating conditions of PCR amplification for all the genes studied. Thus, cDNA amplification was performed in comparative and semiquantitative conditions (Freeman et al., 1999) . Radioactive bands were quantified by video-densitometric scanning (Vilbert Lourmat Imaging). The results for the expression of specific mRNAs are always presented relative to the expression of the control gene (APRT).
Isolation of nuclear extracts
Nuclear extracts were isolated using the Dignam method (Dignam et al., 1983) with the modifications described by Sonnenberg et al. (1989) . Briefly, liver tissues were weighed and homogenized in a Potter Elvehjem homogenizer in 4 volumes (w/v) of buffer A containing 0.25 M sucrose, 15 mM Tris-HCl pH 7.9, 15 mM NaCl, 60 mM KCl, 1 mM EGTA, 5 mM EDTA, 0.15 mM spermine, 0.5 mM spermidine and a mixture of protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride, 1.0 mM dithiothreitol, 5 mg ml À1 aprotinin, 2 mg ml À1 leupeptin). Homogenates were incubated for 10 min on ice and centrifuged (2000 Â g, 10 min, 41C). Pellets were resuspended in 4 vol of buffer B (10 mM Hepes pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl and protease inhibitors as above) and then centrifuged at 4000 Â g, 41C, for 10 min. Supernatants were discarded and pellets were resuspended in 2 vol of buffer C (0.5 M HEPES, pH 7.9, 0.75 mM MgCl 2 , 0.5 M KCl, 12.5% glycerol and protease inhibitors). Homogenates were kept for 30 min at 41C under continuous rotary shaking and then centrifuged at 14,000 Â g for 30 min at 41C. Finally, the resulting supernatants were dialyzed overnight at 41C with buffer D (10 mM Tris-HCl, pH 7.9, 5 mM MgCl 2 , 10 mM KCl, 1.0 mM EDTA, 10% glycerol and protease inhibitors). Nuclear extracts were collected in microfuge tubes and stored in aliquots at À801C. The protein concentration of the nuclear extracts was determined by the method of Bradford (1976) .
Electrophoretic mobility shift assays (EMSA)
The DNA sequences of the double-stranded oligonucleotides used were: consensus binding site of PPAR response element, 5 0 -CAAAACTAGGTCAAAGGTCA-3 0 , consensus binding site of HNF-4 response element 5 0 -CTCAGCTTGTACTTT GGTACAACTA-3 0 , mutant HNF-4 response element 5 0 -CTC AGCTTCTACTTAGGTACAACTA-3 0 (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) and LXR response element, 5 0 -GCTTTGGTCACTCAAGTTCAAGTTA-3 0 . Oligonucleotides were labeled in the following reaction: 1 ml of oligonucleotide (20 ng ml À1 ), 2 ml of 5 Â kinase buffer, 5 U. of T4 polynucleotide kinase and 3 ml of [g-32 P] ATP (3000 Ci mmol
À1
at 10 mCi ml
, Amersham) incubated at 371C for 1 h. The reaction was stopped by adding 90 ml of TE buffer (10 mM Tris-HCl pH 7.4 and 1 mM EDTA). To separate the labeled probe from the unbound ATP, the reaction mixture was eluted in a Nick column (Amersham Biosciences, Sant Cugat, Spain) following the manufacturer instructions. Crude nuclear proteins 4 mg were incubated for 10 min on ice in binding buffer (10 mM Tris-HCl pH 8.0, 25 mM KCl, 0.5 mM DTT, 0.1 mM EDTA pH 8.0, 5% glycerol, 5 mg ml À1 BSA and 50 mg ml À1 poly(dI-dC)), in a final volume of 15 ml. Labeled probe (approximately 55,000 c.p.m.) was added and the reaction was incubated for 20 min at room temperature. Where indicated, specific competitor oligonucleotide was added before the addition of labeled probe and incubated for 15 min on ice. Moreover, for supershift assays, antibodies were added before incubation with labeled probe for a further 30 min at 41C. Protein-DNA complexes were resolved by electrophoresis at 41C on a 5% acrylamide gel and subjected to autoradiography. Antibodies against PPARa (sc-1985x), 
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LXRa (sc-1206x), HNF-4 (sc-6556x), RXRa (sc-553x), Octamer motif-1 transcription factor (Oct-1) (sc-232x) and normal rabbit IgG were from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.).
Western-blot analysis
Crude nuclear extract (40 mg for PPAR-a, HNF-4, COUP-TFII and PGC-1 determination, and 80 mg for LXRa determination) from liver were subjected to 10% SDSpolyacrylamide gel electrophoresis. Proteins were then transferred to Immobilon polyvinylidene difluoride transfer membranes (Millipore, Bedford, MA, U.S.A.) and blocked for 1 h at room temperature with 5% non-fat dry milk in 25 mM TrisCl, pH 8.3, 140 mM NaCl, 2 mM KCl and 0.05% Tween 20 (NFDM TBS-Tween). Membranes were then incubated overnight at 41C with the primary polyclonal antibody raised against PPARa (dilution 1 : 1000) (Lemberger et al., 1996) , HNF-4 (dilution 1 : 500, sc-6556), COUP-TFII (1 : 200, sc-6578), PGC-1 (1 : 100, sc-13067) or against LXRa (dilution 1 : 500, sc-1206) (antibodies from Santa Cruz Biotechnology) in 5% NFDM TBS-Tween. Detection was achieved using the ECL chemiluminescence kit for Horseradish peroxidase (Biological Industries, Israel). To confirm the uniformity of protein loading in each lane, the blots were stained with Ponceau S (Roma´n et al., 2000) . The size of detected proteins was estimated using protein molecular-mass standards (Invitrogen, Life Technologies).
Statistics
Results are the mean of n values7standard deviation. Plasma samples were assayed in duplicate. Treatment-related significant differences between results from sex-matched groups were established by an unpaired t-test, using the computer program GraphPad-InStat (GraphPad Software V2.03). When the variance was not homogeneous, a non-parametric test was performed (Mann-Whitney test). Statistical significance was set at Po0.05. When using pooled samples, as in Western and EMSA assays, experiments were performed at least twice to confirm the observed changes.
Results
Atorvastatin administration partially prevents the lipid metabolic disturbances associated with old age in old male but not in old female Sprague-Dawley rats
Old Sprague-Dawley rats are hypercholesterolemic and hypertriglyceridemic, present higher plasma concentrations of NEFA, insulin and leptin than younger animals and accumulate more triglycerides and cholesteryl-esters in liver tissue (Sanguino et al., 2004a, b) . These changes are partially linked to a marked decrease in hepatic PPARa expression and activity caused by old age and thus to the reduction in the expression of PPARa-target genes coding for proteins involved in the oxidative handling of fatty acids. The oral administration of atorvastatin for 21 days to 18-month-old male rats partially prevented the age-related decrease in hepatic PPARa. Thus, PPARa mRNA and protein were increased by 2.2-and 1.6-fold, respectively, compared with the values obtained in age-matched controls (Figure 1a and b). In samples of skeletal muscle and heart from atorvastatin-treated males, PPARa mRNA also showed a tendency to increase by 28 and 35%, respectively, compared with age-matched controls, although the differences were not significant (data not shown).
Incubation of rat hepatic nuclear extracts with a PPRE oligonucleotide yielded four specific bands (bands 1-4 in Figure 1c ) that were completely competed by incubation with unlabeled oligonucleotide. Incubation with a PPARa antibody decreased the intensity of the four bands and produced a supershifted band (arrow in Figure 1c ) from band 2, indicating the participation of PPARa protein in the formation of shifted bands 1-4. When nuclear extracts were incubated in the presence of an RXRa antibody, the intensity of bands 1 and 2 slightly decreased, pointing to the participation of the RXRaPPARa heterodimer in the formation of at least bands 1 and 2. According to the enhanced expression of PPARa produced by ATV administration, the intensity of the four specific PPARa bands was clearly increased when the EMSA assay was performed with nuclear samples from ATV-treated old male rats, especially that of band 1 (nine-fold versus age-matched controls values, Figure 1d ).
ATV administration to old female Sprague-Dawley rats increased the amount of PPARa protein by 42% compared with age-matched controls (Figure 1b) , but failed to modify PPARa mRNA and binding activity (Figure 1a and d) .
When the liver expression of L-CPT-I and MCAD, two well-known PPARa-target genes, was determined, only the mRNA for MCAD was significantly increased (3.5-fold) in ATV-treated male rats compared with age-matched controls (Figure 2b ). However, ATV significantly increased (21%) fatty acid b-oxidation activity in hepatic samples from treated male rats (Figure 2c ). Neither the expression of the PPARa-target genes studied nor fatty acid b-oxidation activity was significantly modified in livers of ATV-treated female rats (Figure 2 ).
Probably as a consequence of enhanced fatty acid oxidation, ATV markedly reduced the hepatic concentration of cholesteryl-esters (À48%) and triglycerides (À41%) in treated males, compared with age-matched controls (Table 2) . Furthermore, ATV-treated males showed significantly lower plasma concentrations of glucose (À18%), NEFA (À39%) and triglycerides (À35%) than age-matched controls (Table 3) .
Except for a significant reduction (32%) in the plasma concentration of NEFA, none of the analytes determined in the plasma and liver tissue of old females differed from agematched control values as a result of ATV treatment (Tables 2  and 3 ). Furthermore, the mRNA levels of DGAT1 and DGAT2, which are markedly increased in liver of old female rats (Sanguino et al., 2004a) , were unchanged by ATV treatment (Table 4) . Plasma concentrations of cholesterol, insulin and leptin remained unchanged after ATV administration to old male and female rats (Table 3) .
The lack of effect of ATV on old female rats was not due to differences in the pharmacokinetic disposition of ATV between old male and female rats, since the increase in the hepatic level of mRNA for 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (Roglans et al., 2002a, b) , the primary molecular target for atorvastatin activity, was practically identical in males and females (1.8-, and 1.7-fold increase for old male and female rats, respectively, versus the values presented by age-matched controls) (Table 4) .
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Atorvastatin reverses PPARa and HNF-4 reduction ATV administration reverses age-related changes in LXRa expression and activity in livers of old-male Sprague-Dawley rats
We have previously shown that liver samples from old male Sprague-Dawley rats, but not females, had a higher content of LXRa protein than young males, while their specific binding to an LXR-response element oligonucleotide was lower (Sanguino et al., 2004a) . These changes were related to the increased burden of fatty acids in the liver of old males. In agreement with the increased fatty acid oxidative capacity of livers from ATV-treated old males, the amount of LXRa protein in hepatic samples from these rats was 22% lower than in agematched controls (Figure 3a) . The incubation of rat hepatic nuclear extracts with an LXRE oligonucleotide probe yielded a single, specific band that disappeared in the presence of increasing amounts of cold probe and contained LXRa protein, as it was supershifted in the presence of a specific LXRa antibody (Figure 3b ). Hepatic nuclear extracts from ATV-treated males showed a 3.4-fold increase in the intensity of the specific band corresponding to the binding activity of LXRa (Figure 3c ). The LXRa protein and binding activity of livers from ATV-treated females were practically unchanged (Figure 3 ).
ATV increases hepatic HNF-4 content and binding activity in old male rats
Two transcription factors, namely HNF-4 and COUP-TFII, participate in the transcriptional regulation of the PPARa gene, either by increasing -HNF-4-or by decreasing -COUP-TFII -its expression (Hayhurst et al., 2001; Pineda Torra et al., 2002) . Moreover, coactivator protein PGC-1, in addition to being one of the main coactivators interacting with PPARs, participates, together with HNF-4, in the transcriptional regulation of many genes involved in energy metabolism (Puigserver & Spiegelman, 2003) . To determine the mechanism mediating the ATV-driven increase in liver PPARa, we first tested whether old age affects the expression of these proteins in hepatic samples from 18-month-old male and female rats. While liver COUP-TFII protein content was not affected by age (data not shown), HNF-4 and PGC-1 protein contents were reduced by 74 and 77%, respectively, exclusively in the liver of old males (Figure 4 ), without age-related changes in the liver of old females. Although ATV administration to old male rats did not modify the hepatic expression of PGC-1 (data not Figure 1 (a) Relative levels of PPARa mRNA in hepatic samples from male and female 18-month-old rats treated (ATV) or untreated (CTR) with ATV, 10 mg kg À1 day À1 , for 21 days. Each bar represents the mean7s.d. of values from five animals. A representative autoradiography on the right-hand side of the figure shows the bands corresponding to PPARa mRNA and that of the aprt gene, used as an internal control in the PCR reaction to normalize the results, from liver samples of two animals from each treatment group. # Po0.01 versus values presented by sex-matched CTR rats. (b) Western blot of PPARa in hepatic samples from CTR-and ATV-treated 18-month-old rats. In each line, 40 mg of protein from a pool of liver nuclear extracts from six animals was loaded; the amount of protein loaded was confirmed by the Bradford method. Moreover, the uniformity of protein loading in each lane was assessed by staining the blots with Ponceau S. A.U.: arbitrary units; for each sex, the intensity of the band corresponding to CTR rats was set to 1 A.U. (c) EMSA assay showing the binding of hepatic nuclear extracts (NE) obtained from young rats to a PPRE oligonucleotide. Oct-1 antibody was used to demonstrate that the changes in the intensity of shifted bands produced by the specific PPARa and RXRa antibodies were not due to unspecific interference by the presence of immunoglobulin proteins in the incubation medium. (d) Representative EMSA autoradiography showing the specific bands 1-4 formed with hepatic nuclear extracts from CTR-and ATV-treated 18-month-old rats. In each line, 4 mg of protein from a pool of liver nuclear extracts from six animals was loaded. f.i.: fold induction.
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Atorvastatin reverses PPARa and HNF-4 reduction shown), it increased the amount of HNF-4 protein by 95% (Figure 5a ). Incubation of rat hepatic nuclear extracts with an HNF-4 response element oligonucleotide probe yielded a single, specific band that disappeared in the presence of increasing amounts of cold probe and contained HNF-4 protein, as it was supershifted in the presence of a specific HNF-4 antibody (Figure 5b ). The increase in liver HNF-4 protein produced by ATV was accompanied by a two-fold increase in the intensity of the specific HNF-4-shifted band obtained with nuclear extracts from ATV-treated old male rats (Figure 5c ).
Discussion
18-month-old rats are at a cutoff point for advanced age (Ferrari et al., 2003) . Partially as a consequence of an agerelated reduction in their hepatic PPARa content and activity, they display a set of phenotypic characteristics related to lipid 
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Atorvastatin reverses PPARa and HNF-4 reduction and glucose metabolism that are common to middle-aged humans with the polymetabolic syndrome (Grabiely et al., 2002; Sanguino et al., 2004a, b) . As recently reported by Ford et al. (2002) , the prevalence of the polymetabolic syndrome in an adult U.S. population increases from 6.7% among participants aged 20-29 years to 43.5% for participants aged 60-69 years, with a similar age-adjusted prevalence in men (24%) and women (23.4%). Although it remains to be determined if a similar age-dependent deficit in hepatic PPARa is partially responsible for this condition in humans, our results suggest that ATV prevents this age-related PPARa deficit, thus avoiding many of the disarrangements associated with the metabolic syndrome. In contrast to the clinical use of ATV, our results reveal a marked dichotomy in the response to ATV administration between old male and female rats, senescent females being practically resistant to the metabolic effects of ATV. This difference is more striking if we consider that the primary molecular target of ATV, HMG-CoA reductase (Lea & Mctavish, 1997) , is equally affected in both sexes, as shown by the increases in its specific mRNA in liver samples of treated animals (Table 4) (Roglans et al., 2002a, b) . It is widely accepted that, in rodent species, the triglyceride-lowering effect of statins correlates with efficacy in LDL animal models and is dependent upon inhibition of the enzyme HMG-CoA reductase (Krause & Newton, 1995) . Whatever the molecular mechanism responsible for the differential response to ATV between old male and female rats, our results indicate that this assumption is not completely true, and that triglyceride lowering, at least in the case of ATV, is directly due to the activation by ATV of the hepatic fatty acid catabolizm mediated by PPARa. This occurs in old male rats, as shown in the present report, and has been demonstrated in other , for 21 days. In each line, 80 mg of protein from a pool of liver nuclear extracts from six animals was loaded; the amount of protein loaded was confirmed by the Bradford method. Moreover, the uniformity of protein loading in each lane was assessed by staining the blots with Ponceau S. A.U.: arbitrary units; for each sex, the intensity of the band corresponding to CTR rats was set to 1 A.U. (b) EMSA assay showing that the binding of hepatic nuclear extracts (NE) obtained from young rats to a LXRE oligonucleotide yields a single specific band (arrow). Oct-1 antibody was used to demonstrate that the effect of LXRa antibody was not due to unspecific interference caused by the presence of immunoglobulin proteins in the incubation medium. (c) EMSA autoradiography showing the specific LXRa band (see arrow) corresponding to hepatic samples from CTR-and ATV-treated 18-month-old rats. In each line, 4 mg of protein from a pool of liver nuclear extracts from six animals was loaded. A.U.: arbitrary units; for each sex, the intensity of the band corresponding to CTR rats was set to 1 A.U. 
Atorvastatin reverses PPARa and HNF-4 reduction experimental designs, for example, the sucrose-fed rat (Funatsu et al., 2002) and the fructose-fed rat (Roglans et al., 2002a) . Furthermore, there is a crosstalk between PPARa and estrogen receptors, each receptor inhibiting the transactivating activity of the other (Keller et al., 1995; Linde´n et al., 2001) . As 18-month-old female rats have three times more 17b-estradiol in plasma than males (Sanguino et al., 2004a) , the proportionally increased estrogenic activity, with regard to a decreased hepatic PPARa activity, may account for the lack of response of old female rats to ATV administration. Plasma NEFA was the only analyte equally affected by ATV in both sexes. As ATV modifies the expression of the acylation-stimulating protein in white adipose tissue (Roglans et al., 2002a) , we cannot discard that the reduction in plasma NEFA is due to the effect of ATV on extra-hepatic tissues like muscle and white adipose tissue. Statins exert two differentiated effects on PPARa: (i) They increase PPARa transcriptional activity, probably by indirectly inhibiting the intracellular Rho-signaling pathway (Martin et al., 2001; Inoue et al., 2002) , and (ii) they increase PPARa expression, both ex vivo, in cultured epithelial cells (Inoue et al., 2000) , and in vivo, as reported in the fructose-fed rat model of hypertriglyceridemia (Roglans et al., 2002a) . The mechanism involved in the latter effect is unknown. Our work indicates that ATV also reverses the age-related reduction of hepatic PPARa and suggests a possible mechanism for the statin-mediated induction of PPARa expression, involving the transcription factor HNF-4. We show that ageing, at least in male rats, shifts the hepatic balance between a transcriptional activator of PPARa expression, HNF-4, and a transcriptional inhibitor of PPARa expression, COUP-TFII, by markedly reducing the expression of the former. Given that the rat PPARa promoter contains several DR1-HNF-4 response elements, the age-related change in rat hepatic HNF-4 expression and activity may contribute to the age-related reduction in hepatic PPARa expression. Thus, the partial restoration of the hepatic expression and binding activity of HNF-4 caused by ATV administration may be one of the mechanisms enhancing the liver expression and activity of PPARa observed in old male rats treated with ATV. We do not know why ATV administration did not affect PGC-1 expression but, given that PGC-1 participates in the control of the expression of the L-CPT-I gene (Louet et al., 2002) , this lack of effect may explain why ATV treatment did not increase L-CPT-I mRNA, although it increased liver PPARa. Furthermore, we do not know at this moment why there are no age-related changes in HNF-4 and PGC-1 expression in senescent female rats.
In conclusion, ATV administration to old male rats prevents the age-related metabolic changes associated with the reduction in hepatic PPARa expression and activity. Moreover, we detected marked gender-related differences in the drug response of old rats, senescent females being practically unresponsive to ATV administration. À1 day À1 , for 21 days. In each line, 40 mg of protein from a pool of liver nuclear extracts from six animals was loaded; the amount of protein loaded was confirmed by the Bradford method. Moreover, the uniformity of protein loading in each lane was assessed by staining the blots with Ponceau S. A.U.: arbitrary units; the intensity of the band corresponding to CTR rats was set to 1 A.U. (b) EMSA assay showing that the binding of hepatic nuclear extracts (NE) obtained from 18-month-old male rats to a HNF-4 response element oligonucleotide produces a single band (see arrow).
IgGs were used to demonstrate that the disappearance of the HNF-4 band was not due to unspecific interference caused by the presence of immunoglobulin proteins in the incubation medium. (c) EMSA autoradiography showing the specific HNF-4 band (see arrow) corresponding to hepatic samples from CTR-and ATV-treated 18-month-old male and female rats. In each line, 4 mg of protein from a pool of liver nuclear extracts from six animals was loaded. A.U.: arbitrary units; the intensity of the band corresponding to CTR rats was set to 1 A.U.
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